



COPD UK 2027

CHANGING THE COURSE OF COPD

Two-day provisional clinical and scientific programme
1st and 2nd July 2027

Date: 5th October 2026

Day 1 – Thursday, 1st July 2026

TIME	CLINICAL / PLENARY ROOM	TRANSLATIONAL / PARALLEL ROOM
08:30-09:00	Registration, exhibition and coffee	
09:00-09:15	Welcome to COPD UK 2027	
09:15-10:00	OPENING PLENARY BTS statement discussion	
10:00-10:30	Coffee, exhibition and poster viewing	
10:30-11:20	CLINICAL PARALLEL 1 COPD care that works for patients and the NHS Primary-secondary-community integration; neighbourhood care; hospital at home/virtual care; service models with demonstrable outcomes and lessons for implementation.	TRANSLATIONAL SCIENCE PARALLEL 1 The COPD airway: alarmins and small-airway disease Can targeting epithelial danger signals and small-airway responses alter disease progression?
11:20-12:00	PLENARY 2 Can we prevent COPD? Changing the trajectory before established disease Early/pre-COPD; lung-function trajectories; risk factors and opportunities for earlier intervention.	
12:00-13:00	INDUSTRY SYMPOSIUM 1 HCP industry symposium.	INDEPENDENT SCIENTIFIC SESSION 1 Discovery science in COPD: explain your technique Genetics and genomics; exosomes; spatial biology; the lung cell atlas and multiomics - what each technique can show and what it is teaching us about COPD.
13:00-14:00	Lunch, exhibition and poster viewing	
14:00-14:45	PLENARY 3 Acute COPD: an opportunity to change the 90-day trajectory Exacerbation phenotyping; treatment failure; steroid burden; early post-discharge risk and prevention of recurrence.	

TIME	CLINICAL / PLENARY ROOM	TRANSLATIONAL / PARALLEL ROOM
15:00-16:00	INDUSTRY SYMPOSIUM 2 HCP industry symposium.	INDEPENDENT SCIENTIFIC SESSION 2 Mucus in COPD: from discovery science to measurable endpoints Mucus rheology; ciliary function; mucus composition; and how mucus biology can inform what early-phase studies should measure.
16:00-16:30	Coffee, exhibition and poster viewing	
16:30-17:20	CLINICAL PARALLEL 2 The failing lung: respiratory failure in COPD from hospital to home Acute NIV; home mechanical ventilation/HOT-HMV; oxygen and high-flow therapy, including the high-flow oxygen clinical statement; selecting patients and changing outcomes.	TRANSLATIONAL SCIENCE PARALLEL 2 Why does COPD progress? Disease trajectories; environmental exposures including air pollution; ageing and senescence; remodelling/regeneration; exacerbation-driven progression.
17:20-18:00	HIGHLIGHTS FROM COPD UK RESEARCH- COPD Clinical Trials Led by early career researchers and healthcare professionals: key clinical and translational COPD UK research highlights and trial updates.	
18:00-18:30	SCIENTIFIC ABSTRACT ORAL PRESENTATIONS Selected scientific abstracts presented as short oral communications, leading into general poster viewing.	
18:30 onwards	Poster discussion, networking, exhibition and evening reception/dinner	

Day 2 – Friday, 2nd July 2027

TIME	CLINICAL / PLENARY ROOM	TRANSLATIONAL / PARALLEL ROOM
08:00-08:30	Coffee, exhibition and poster viewing	
08:30-09:00	PLENARY 1 Changing COPD outcomes beyond the lung Multimorbidity in COPD: cardiopulmonary risk, obesity and diabetes, psychological health and bone health - and why COPD outcomes cannot be considered in isolation.	

TIME	CLINICAL / PLENARY ROOM	TRANSLATIONAL / PARALLEL ROOM
09:00-10:00	INDUSTRY SYMPOSIUM 3 HCP industry symposium.	BUILDING A CAREER IN COPD RESEARCH Brief whole-room introduction followed by mentoring breakout tables selected at registration: clinical academic; basic/translational scientist; NMAHP/MDT clinical academic; developing independence, fellowships and grants.
10:00-10:30	Coffee, exhibition and poster viewing	
10:30-11:10	CLINICAL PARALLEL 1 Starting biologics in COPD: from eligible patient to first prescription Patient identification; eligibility and optimisation; service pathways; monitoring and reassessment.	TRANSLATIONAL SCIENCE PARALLEL 1 Infection in COPD: microbiome, mycobion and virome Bacteria, fungi and viruses in COPD: speakers each present a key pathogen and its implications for susceptibility, host response and exacerbation risk.
11:10-11:50	NURSING AND ALLIED HEALTH PROFESSIONAL SESSION Nurse- and AHP-led COPD practice and research, highlighting innovation and clinical impact.	TRANSLATIONAL SCIENCE PARALLEL 2 What comes after current biologics? Emerging disease-modifying targets and how mechanistic discovery can be translated into the next generation of COPD trials.
11:50-12:50	INDUSTRY SYMPOSIUM 4 HCP industry symposium.	INDEPENDENT SCIENTIFIC SESSION 3 Modelling COPD in the laboratory: explain your technique Pre-clinical models compared: organoids and air-liquid interface cultures, lung-on-a-chip and precision-cut lung slices - strengths, limitations and what each can tell us.
12:50-13:30	Lunch, exhibition and final poster viewing	
13:30 -14:10	PLENARY 2 Changing the outcome of inherited COPD: Alpha-1 antitrypsin deficiency -Rewriting the gene, recording the evidence. From gene and RNA editing to the EARCO registry.	
14:10-14:50	MIKE MORGAN LECTURE / CLOSING PLENARY Changing the course of COPD: the next decade A forward-looking keynote spanning prevention, disease modification, acute care, multimorbidity and implementation.	
14:50-15:15	Conference close and COPD UK 2028	

Declaration of Sponsorship

This event is sponsored by pharmaceutical and healthcare companies who have contributed funding towards the event in return for exhibition space and/or sponsored speaker sessions. Sponsorship funds have been used directly to support the delivery of the event including venue fees and daytime catering. No sponsorship funds have been used to support the evening dinner, nor the poster awards ceremony. Sponsors have had no editorial input into or control over the agenda, content development or choice of neither speakers nor opportunity to influence except for the sponsored symposia presentations.